Pharsight

1. List of Axiron drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8784878	ELI LILLY AND CO	Transdermal delivery rate control using amorphous pharmaceutical compositions	Jul, 2023 (5 months from now)
US8993520	ELI LILLY AND CO	Method and composition for transdermal drug delivery	Jun, 2026 (3 years from now)
US9180194	ELI LILLY AND CO	Method and composition for transdermal drug delivery	Jun, 2026 (3 years from now)
US8419307	ELI LILLY AND CO	Spreading implement	Feb, 2027 (4 years from now)
US8807861	ELI LILLY AND CO	Spreading implement	Feb, 2027 (4 years from now)
US9289586	ELI LILLY AND CO	Spreading implement	Feb, 2027 (4 years from now)
US8435944	ELI LILLY AND CO	Method and composition for transdermal drug delivery	Sep, 2027 (4 years from now)

Drugs and Companies using TESTOSTERONE ingredient

Market Authorisation Date: 23 November, 2010

Treatment: A method of transdermally delivering testosterone; A method of increasing the testosterone blood level of an adult male subject in need thereof; A method of increasing the testosterone blood level of a person in need thereof; A method of transdermal administration of a physiologically active agent to a subject.

Dosage: SOLUTION, METERED;TRANSDERMAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
30 mg/1.5 mL	29 Jan, 2013	1	07 Aug, 2017	19 Feb, 2017	Extinguished

Strength	Dosage	Availability
30MG/1.5ML ACTUATION	SOLUTION, METERED;TRANSDERMAL	Discontinued

2. List of Baqsimi drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6938798	ELI LILLY AND CO	Fluid or powdery product dispensing device	Jan, 2022 (1 year, 30 days ago)
US10213487	ELI LILLY AND CO	Nasal powder formulation for treatment of hypoglycemia	Feb, 2036 (13 years from now)
US10894133	ELI LILLY AND CO	Device for dispensing a fluid product	Jan, 2038 (14 years from now)
US10765602	ELI LILLY AND CO	Medication delivery systems and methods	Sep, 2039 (16 years from now)

Exclusivity	Exclusivity Expiration
New Product (NP)	Jul 24, 2022

Drugs and Companies using GLUCAGON ingredient

Market Authorisation Date: 24 July, 2019

Treatment: Treatment of severe hypoglycemia in patients with diabetes

Dosage: POWDER;NASAL

Strength	Dosage	Availability
3MG	POWDER;NASAL	Prescription

3. List of Mounjaro drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9474780	ELI LILLY AND CO	GIP and GLP-1 co-agonist compounds	Jan, 2036 (12 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8734394	ELI LILLY AND CO	Automatic injection device with delay mechanism including dual functioning biasing member	Feb, 2031 (8 years from now)
US9402957	ELI LILLY AND CO	Automatic injection device with delay mechanism including dual functioning biasing member	Jun, 2031 (8 years from now)
US11357820	ELI LILLY AND CO	GIP/GLP1 agonist compositions	Jun, 2039 (16 years from now)

Exclusivity	Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	May 13, 2027

Drugs and Companies using TIRZEPATIDE ingredient

NCE-1 date: May, 2026

Market Authorisation Date: 13 May, 2022

Treatment: Mounjaro is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus

Dosage: SOLUTION;SUBCUTANEOUS

Strength	Dosage	Availability
2.5MG/0.5ML (2.5MG/0.5ML)	SOLUTION;SUBCUTANEOUS	Prescription
5MG/0.5ML (5MG/0.5ML)	SOLUTION;SUBCUTANEOUS	Prescription
7.5MG/0.5ML (7.5MG/0.5ML)	SOLUTION;SUBCUTANEOUS	Prescription
10MG/0.5ML (10MG/0.5ML)	SOLUTION;SUBCUTANEOUS	Prescription
12.5MG/0.5ML (12.5MG/0.5ML)	SOLUTION;SUBCUTANEOUS	Prescription
15MG/0.5ML (15MG/0.5ML)	SOLUTION;SUBCUTANEOUS	Prescription

4. List of Olumiant drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8158616	ELI LILLY AND CO	Azetidine and cyclobutane derivatives as JAK inhibitors	Jun, 2030 (7 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8420629	ELI LILLY AND CO	Azetidine and cyclobutane derivatives as JAK inhibitors	Mar, 2029 (6 years from now)
US9089574	ELI LILLY AND CO	Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections	Nov, 2032 (9 years from now)
US11045474	ELI LILLY AND CO	Antiviral JAK inhibitors useful in treating or preventing coronaviridae infections	Nov, 2032 (9 years from now)
US9737469	ELI LILLY AND CO	Methods for treating hair loss disorders	Mar, 2033 (10 years from now)

Exclusivity	Exclusivity Expiration
New Indication (I)	May 10, 2025
New Chemical Entity Exclusivity (NCE)	May 31, 2023

Drugs and Companies using BARICITINIB ingredient

NCE-1 date: May, 2022

Market Authorisation Date: 31 May, 2018

Treatment: Treatment of rheumatoid arthritis; Treatment of coronavirus disease 2019 (covid-19) in hospitalized adults requiring supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ecmo); Treatment of adult patients with severe alopecia areata

Dosage: TABLET;ORAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
1 mg and 2 mg	31 May, 2022	2		08 Jun, 2030

Strength	Dosage	Availability
1MG	TABLET;ORAL	Prescription
2MG	TABLET;ORAL	Prescription

5. List of Reyvow drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7423050	ELI LILLY AND CO	Pyridinoylpiperidines as 5-HT1F agonists	Apr, 2025 (2 years from now)
US11053214	ELI LILLY AND CO	Compositions and methods related to pyridinoylpiperidine 5-HT1F agonists	Dec, 2037 (14 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8748459	ELI LILLY AND CO	Pyridinoylpiperidines as 5-HT1F agonists	Mar, 2023 (a month from now)

Exclusivity	Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	Jan 31, 2025

Drugs and Companies using LASMIDITAN SUCCINATE ingredient

NCE-1 date: February, 2024

Market Authorisation Date: 31 January, 2020

Treatment: Acute treatment of migraine

Dosage: TABLET;ORAL

Strength	Dosage	Availability
EQ 50MG BASE	TABLET;ORAL	Prescription
EQ 100MG BASE	TABLET;ORAL	Prescription
EQ 200MG BASE	TABLET;ORAL	Discontinued

6. List of Verzenio drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7855211	ELI LILLY AND CO	Protein kinase inhibitors	Dec, 2029 (6 years from now)

Exclusivity	Exclusivity Expiration
New Chemical Entity Exclusivity (NCE)	Sep 28, 2022
New Patient Population (NPP)	Oct 12, 2024
New Indication (I)	Oct 12, 2024

Drugs and Companies using ABEMACICLIB ingredient

NCE-1 date: September, 2021

Market Authorisation Date: 28 September, 2017

Treatment: In combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of postmenopausal women with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative advanced or metastatic breast cancer; In combination with fulvestrant for the treatment of women with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her2)-negative advanced or metastatic breast cancer with disease progression following endocrine therapy; As monotherapy for the treatment of adult patients with hr-positive, her2-negative advanced or metastic breast cancer with disease progression following endocrine therapy and prior chemotherapy in the metastatic setting; In combination with an aromatase inhibitor as initial endocrine-based therapy for treatment of postmenopausal women with hormone receptor (hr)-positive, human epidermal growth factor receptor 2 (her-2)-negative advanced or metastatic breast cancer; In combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant treatment of adult patients with hr-positive, her2-negative, node-positive, early breast cancer at high risk of recurrence and a ki-67 score >=20%; In combination with fulvestrant for the treatment of adult patients with hr-positive, human epidermal growth factor receptor 2 (her2)-negative advanced or metastatic breast cancer with disease progression following endrocrine therapy; In combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of postmenopausal women, and men with hr-positive, human epidermal growth factor receptor 2 (her2)-negative advanced or metastatic breast cancer

Dosage: TABLET;ORAL